Drug intelligence / Profile preview

DVD-R

Development stage: Unknown
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Oral

Overview

DVD-R is a combination drug regimen used for the treatment of relapsed/refractory multiple myeloma (MM). It comprises four active agents: pegylated liposomal doxorubicin (an anthracycline), bortezomib (a proteasome inhibitor), dexamethasone (a corticosteroid), and lenalidomide (an immunomodulatory drug). This multi-agent approach targets various pathways involved in myeloma cell proliferation and survival, aiming to enhance efficacy and tolerability. Clinical studies have demonstrated that the DVD-R regimen is well tolerated and produces high response rates in patients with relapsed/refractory MM.

Targets

26S proteasomeCRBN (Cereblon)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on DVD-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DVD-R.

Explore the full profile